IGF-1 Elevation Studies Research has documented significant and prolonged IGF-1 increases following peptide blend administration: 1.5- to 3-fold elevation of plasma IGF-1 concentrations lasting 9-11 days after single dose Multiple doses resulted in cumulative effects with IGF-1 remaining elevated for up to 28 days IGF-1 increases correlated with growth hormone pulse amplitude and frequency Liver-mediated IGF-1 production served as primary mediator of downstream anabolic effects Musculoskeletal Research Bone Formation and Density Investigations in rat models have examined the blends effects on bone metabolism and skeletal growth: Dose-dependent increases in longitudinal bone growth rate from 42 mcm/day (vehicle) to 52 mcm/day at highest dose Ipamorelin demonstrated ability to counteract glucocorticoid-induced bone formation suppression in adult rats Preserved bone mineral content and improved trabecular architecture in preclinical models No adverse effects on femur or tibia length or bone composition parameters Bone formation markers and osteoblast activity increased in animal models receiving the peptide combination, suggesting potential applications in osteoporosis research
However, like any compound, side effects may occur depending on individual sensitivity, dosage, and administration method
Researchers continue to investigate how these complementary pathways interact during normal tissue maintenance and physiological adaptation
J Neurochem 73:889902, PMID: 10461878 Varga V, Janky R, Marnela KM, Gulys J, Kontro P, Oja SS (1989) Displacement of excitatory amino acid receptor ligands by acidic oligopeptides
Mechanism of Action: It may help modulate the inflammatory response by influencing various signaling pathways and reducing the production of pro-inflammatory cytokines
